TABLE 5.

Failures of TSH

Patients Failing TSH (n = 21) and Crossover to ALPPS (n = 13)		P
Failing due to tumor progression (n = 8)
PVL patients	(2/14)14%	0.81
PVE patients	(6/35)17%
Failing due to insufficient growth (n = 13)
PVL patients	(5/14)36%	0.36
PVE patients	(8/35)23%
Baseline volume FLR*‡ (mL)	276 ± 77
Baseline volume sFLR† (%)	16.3 ± 4.5
Volume 7 d FLR (mL)	342 ± 89
Volume 7 d sFLR (%)	20.4 ± 5.2
KGR days 0–28	1.1 ± 0.6
Volume increase (%) days 0–7	28.6 ± 10.3
Crossover from TSH to ALPPS (n = 13)
Successful ALPPS	12
Days from First intervention to ALPPS 1	85 ± 82
Complication ≥3a (%)	27
Negative surgical margin in the liver (%)	67
90-d mortality after final intervention	0

^*Future liver remnant, the part of the liver that will remain after final resection.

^†sFLR% relative volume in relation to the patients estimated total liver volume.

^‡Plus–minus values are means ± SD.

PVE indicates portal venous embolization; PL, portal ligation; FLR, future liver remnant; KGR, kinetic growth rate, absolute increase in volume in % in 1 week.